• Phase 2 Myeloma Trial for Investigational CAR T-cell Therapy bb2121 Completes Enrollment
  • AMG 420 Immunotherapy Shows Promise in Relapsed or Refractory Multiple Myeloma
  • Researchers Identify 3 Genetic Alterations Associated with Higher Risk of Myeloma in African-Americans
  • Seattle Genetics Initiates Phase 1 Trial of SEA-BCMA in Relapsed or Refractory Multiple Myeloma Patients
  • Darzalex Extends Time to Disease Progression, Death Among Newly Diagnosed Multiple Myeloma Patients, Phase 3 Trial Shows
  • Excessive RNA Editing Linked to Myeloma Progression, Treatment Resistance, Study Suggests
  • FDA Grants Poseida’s P-BCMA-101 RMAT Status for Treatment of Multiple Myeloma
  • FDA Clears Way for Trials of FOR46 in Late-stage Multiple Myeloma, Prostate Cancer
  • FDA Approves Empliciti Combination for Relapsed or Refractory Multiple Myeloma
  • Darzalex Add-on Delays Disease Progression or Death in Newly Diagnosed Multiple Myeloma, Phase 3 Trial Shows
  • Myeloma Crowd Launches Online Tool to Help Patients Find Treatment Options, Contribute to Research
  • New Compound Safely Halts Advanced Myeloma Progression in Small Pilot Study